A Phase 2 interventional study of KDS2010 and Placebo in Mild Cognitive Impairment (MCI), Mild Dementia and Alzheimer's Disease, sponsored by NeuroBiogen Co., Ltd. Recruiting at 8 sites in South Korea. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by NeuroBiogen Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one is the 24th largest by planned enrollment of the 57 interventional ones that give a count, is one of 13 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 16 of the 23 other live ones, and was the 62nd registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Japan and 1 more country
Ages 55–85
Deepsonbio · Sites in Korea, Republic of
Ages 55–90
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Argentina and 16 more countries
Ages 60–85
Hoffmann-La Roche · Sites in Korea, Republic of, United States, Argentina and 12 more countries
Ages 50–90
Amyloid Solution Inc · Sites in Korea, Republic of
Ages 19–85 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 94 across the 57 interventional studies, 163 across the 17 observational. Of the 34 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 74 have an industry lead sponsor. The 10 most frequent:
NeuroBiogen Co., Ltd is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
NeuroBiogen Co., Ltd has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
10 of the studies in Cognitive Dysfunction with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT07239310DeepsonbioNeuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease | 2026-12 |
| NCT07334366Pusan National University Yangsan HospitalBroccoli Sprout Extract for Cognitive Function | 2026-12-30 |
| NCT07011680Pusan National University Yangsan HospitalPhospholipid-rich Dairy Extract for Cognitive Function | 2026-12-30 |
| NCT06786676Amyloid Solution IncA Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo-controlled, dose-finding Phase 2a clinical trial will be conducted to evaluate the efficacy and safety of KDS2010 in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild dementia due to Alzheimer's disease.
Based on preliminary efficacy observed in the Phase 1 clinical trial, a clinical trial will be conducted in Korea. Eligible patients diagnosed with MCI or mild Alzheimer's disease will be stratified by disease stage (MCI/mild AD) prior to randomization. Subjects will be randomly assigned in a 1:1:1 ratio to either Treatment Group 1, Treatment Group 2, or the Control Group. The investigational product will be administered orally once daily for a duration of 24 weeks. Approximately 114 subjects will be enrolled, including an estimated 20% dropout rate, with 38 subjects assigned to each group (Treatment Group 1, Treatment Group 2, and Control Group).
The objectives of the study are as follows:
Based on nonclinical and Phase 1 clinical data, KDS2010 will be administered orally once daily at two dose levels: 60 mg and 120 mg.
This Phase 2a, randomized, double-blind, placebo-controlled, dose-finding clinical trial is designed to evaluate the efficacy, safety, and pharmacokinetics of KDS2010, a novel investigational product, reversible monoamine oxidase-B (MAO-B) inhibitor, in patients with Alzheimer's Disease (AD) with Mild Cognitive Impairment (MCI) and Mild Dementia due to Alzheimer's Disease. The clinical trial is conducted at selected sites in Korea.
A total of 114 subjects are planned for the study, with 38 subjects in each of the three groups: two treatment groups (receiving different doses of KDS2010) and a placebo control group. Subjects will be randomized in a 1:1:1 ratio, and the study is designed to allow for a 20% dropout rate. Inclusion criteria require that participants be aged between 50 and 85 years, diagnosed with MCI or mild AD, and amyloid-positive as confirmed by PET scans. Eligible participants must also demonstrate cognitive impairment as indicated by a CDR score between 0.5 and 1.0 and an MMSE score between 21 and 30.
Key exclusion criteria include individuals with cognitive impairment caused by conditions other than AD, those with a history of serious medical conditions such as cardiovascular disease or cancer, and individuals who have used AD-modifying agents or CNS-active drugs within 12 weeks prior to screening.
The primary efficacy endpoint is the change in cognitive function, assessed through the Clinical Dementia Rating-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), and Alzheimer's Disease Assessment Scale-Cognitive 13 (ADAS-Cog13) scores. Secondary efficacy endpoints include changes in daily living activities (measured by the Activities of Daily Living Scale and the Alzheimer's Disease IADL Questionnaire), as well as biomarkers such as tauopathy and Apo-E4. Exploratory endpoints will assess cognitive decline and specific changes in brain imaging (e.g., PET scans) and cerebrospinal fluid biomarkers.
Safety will be evaluated through monitoring adverse events (AEs), vital signs, laboratory tests, ECGs, and psychological assessments, including the Columbia-Suicide Severity Rating Scale (C-SSRS). Pharmacokinetic parameters (AUCtau, Cmax,ss, Cmin,ss, Cav,ss, Tmax,ss, T1/2, and PTF, etc.) will be measured to assess systemic exposure to KDS2010.
Subjects must be aged between 50 and 85 years, diagnosed with MCI or mild AD, and amyloid-positive based on PET scan results. Inclusion criteria also require cognitive impairment as indicated by a CDR score between 0.5 and 1.0 and an MMSE score between 21 and 30. Major exclusion criteria include conditions other than AD that cause cognitive impairment, uncontrolled systemic diseases, and recent use of AD-modifying agents.
The primary aim of the study is to determine the potential of KDS2010 to slow cognitive decline in individuals with early-stage Alzheimer's disease, with secondary and exploratory objectives focused on safety, quality of life, and understanding the drug's pharmacokinetic profile. This study aims to provide important insights into the potential therapeutic benefits of KDS2010 in treating Alzheimer's disease at the early stages of cognitive decline.
The total duration of the study is expected to be approximately 30 months from IRB/IEC approval, with individual subject participation lasting up to 9 months. This trial aims to evaluate the safety, efficacy, and pharmacokinetics of KDS2010 as a potential treatment for early stages of Alzheimer's disease, with the goal of advancing the development of KDS2010 in the treatment of AD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cognitive impairment or dementia due to causes other than Alzheimer's disease
Subjects confirmed during screening to have had the following medical history:
Subjects confirmed during screening to have had the following accompanying disease:
Following laboratory test values at screening:
Subjects who have undergone or require treatment with the following:
However, exceptions are allowed for one-time use of the drugs, such as second-generation H1 antihistamines (e.g., cetirizine, levocetirizine, etc.) or peripheral anticholinergics with no central action (e.g., trospium for treating overactive bladder). But the use is prohibited for at least 3 days from the date of cognitive function evaluation.
The following serotonergic drugs within two weeks before baseline or five times the half-life of the drug (whichever is longer, and patients can be enrolled after wash-out),
Use of strong inducer, CYP3A4 strong inhibitor, CYP2D6 strong inducer, and CYP2D6 strong inhibitor during the screening period
Fertile women or men who are unwilling to use effective * from the date of written consent until 12 weeks after the last administration of the investigational product
*Effective contraception is defined as follows, and at least one method should be used:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A placebo will be administered orally once daily as two tablets per day for 24 weeks. This group will match the investigational drug in appearance but contain no active ingredients to maintain blinding.
Drug: Placebo
KDS2010 60 mg will be administered orally once daily as two tablets per day (one 60 mg KDS2010 tablet and one placebo tablet, 60 mg total) for 24 weeks. This group will receive the active investigational drug to evaluate its safety and efficacy.
Drug: KDS2010
KDS2010 60 mg will be administered orally once daily as two tablets per day (two 60 mg KDS2010 tablets, 120 mg total) for 24 weeks. This group will receive the higher dose of the investigational drug to evaluate its safety and efficacy.
Drug: KDS2010
KDS2010 will be administered orally once daily, two tablets per day, for 24 weeks. Dosage will be either 60 mg or 120 mg depending on the assigned group.
Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, two tablets per day, for 24 weeks.
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) score
Clinical Dementia Rating (CDR) is a tool developed to assess the clinical stages of Alzheimer's disease. CDR 0 indicates "no dementia," CDR 0.5 "questionable," CDR 1 "mild," CDR 2 "moderate," and CDR 3 "severe" dementia. The range for CDR-SB is 0 to 18 points, where higher scores indicate more severe dementia.
Time frame: Screening (-8 Week~), Week 4, Week 8, Week 12, Week 24, Week 26
Time to ≥0.5-point increase in CDR-SB
Time from randomization to the first occurrence of ≥0.5-point increase in CDR-SB score.
Time frame: Up to Week 26
Change from Baseline in Mini-Mental State Examination (MMSE) score
The MMSE is a cognitive function and disease severity assessment composed of 30 items. Each is graded on a 2-point scale where 1 point is awarded for correct performance and 0 points if not performed correctly. Lower total scores on the MMSE indicate cognitive impairment.
Time frame: Screening (-8 Week~), Week 12, Week 24, Week 26
Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13) score
ADAS-Cog13 is a comprehensive tool for the early diagnosis of dementia and the sensitive assessment of disease progression stages. The assessment includes 9 "neuropsychological tests" and 4 "clinical assessments of cognitive damage", totaling 13 items. The higher the total score of the ADAS-Cog, the more it indicates cognitive dysfunction.
Time frame: Screening (-8 Week~), Week 12, Week 24, Week 26
Change from Baseline in Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q-SV) score
The A-IADL-Q is a questionnaire designed to assess impairments in instrumental activities of daily living (IADL) in patients with dementia. The A-IADL-Q-SV is a short version of the A-IADL-Q, consisting of 30 items that assess instrumental daily functioning sensitive to cognitive decline. Each item is rated on a 5-point Likert scale, with higher scores indicating better functional ability.
Time frame: Screening (-8 Week~), Week 12, Week 24
Percentage change from Baseline in plasma and Cerebrospinal Fluid(CSF) biomarkers
Changes in plasma and CSF levels of MAO-B (Monoamine Oxidase B) specific activity, GFAP (Glial Fibrillary Acidic Protein), P-tau181 (Phosphorylated-Tau 181), P-tau217 (Phosphorylated-Tau 217), Aβ-40 (Amyloid beta 40), Aβ-42 (Amyloid beta 42), NfL (Neurofilament Light Chain), BDNF (Brain-derived Neurotrophic Factor), IL-1β (Interleukin-1β), and TNF-α (Tumor Necrosis Factor-α).
Time frame: Screening (-8 Week~), Week 12, Week 24
Percentage change from Baseline in plasma Monoamine Oxidase B (MAO-B) specific activity
Plasma MAO-B specific activity at Week 26 compared to baseline.
Time frame: Screening (-8 Week~), Week 26
Number of subjects with treatment-related Adverse Events (AEs)
AEs will be coded using MedDRA and assessed for severity and causality using CTCAE v5.0. The number of subjects affected and the incidence rates will be presented for each treatment group.
Time frame: Through study completion (approx. 26 weeks)
Change from baseline in systolic and diastolic blood pressure
Blood pressure will be measured in mmHg at each visit.
Time frame: Screening (-8 Week~), Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 26
Change from baseline in pulse rate
Pulse rate will be measured in beats per minute.
Time frame: Screening (-8 Week~), Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 26
Change from baseline in body temperature
Body temperature will be measured using a standard thermometer.
Time frame: Screening (-8 Week~), Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 26
Change from baseline in laboratory test results
Laboratory parameters, including routine hematology, blood chemistry, coagulation, urinalysis, and others, will be measured. Change from baseline will be analyzed.
Time frame: Screening (-8 Week~), Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 26
Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) total score
C-SSRS is used to assess the risk of suicide through interviews with the subject. The scores of each question are summed to range from 0 to 25 points. If "yes" from questions 4 or 5, categorize a subject as high-risk, requiring further evaluation, while other scores indicate a lower risk.
Time frame: Screening (-8 Week~), Week 24
Pharmacokinetic Parameters: Area Under the Plasma Concentration-Time Curve over the dosing interval (τ) (AUCtau) at steady-state
AUCtau is the area under the plasma concentration-time curve over the dosing interval (τ) at steady-state, and it reflects the extent of drug exposure within a dosing cycle.
Time frame: Baseline (Week 0), Week 12
Pharmacokinetic Parameters: Peak Plasma Concentration at Steady State (Cmax,ss)
The highest plasma drug concentration observed during a dosing interval at steady state.
Time frame: Baseline (Week 0), Week 12
Pharmacokinetic Parameters: Minimum Plasma Concentration at Steady State (Cmin,ss)
The lowest plasma drug concentration during a dosing interval at steady state, usually occurring right before the next dose.
Time frame: Baseline (Week 0), Week 12
Pharmacokinetic Parameters: Average Plasma Concentration at Steady State (Cav,ss)
The average plasma concentration over the dosing interval at steady state. Calculated as: Cav, ss = AUCtau/τ
Time frame: Baseline (Week 0), Week 12
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration at Steady State (Tmax,ss)
The time taken to reach the maximum plasma concentration after dosing at steady state.
Time frame: Baseline (Week 0), Week 12
Pharmacokinetic Parameters: Terminal Elimination Half-life (t1/2)
The time required for the plasma concentration of the drug to decrease by half.
Time frame: Baseline (Week 0), Week 12
Pharmacokinetic Parameters: Peak-Trough Fluctuation at Steady State (PTF)
A measure of the fluctuation between the peak (Cmax,ss) and trough (Cmin,ss) plasma concentrations during a dosing interval.
Time frame: Baseline (Week 0), Week 12
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.
Of 42 industry-sponsored phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 22 months is close to that.
Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NeuroBiogen Co., Ltd